Pituitary adenomas are benign neoplasms that account for 10%-15% of all diagnosed intracranial tumours, and they are the most common type of pituitary disorder (Castellanos, Gutierrez et al., 2021;Di Somma et al., 2021;Famini et al., 2011). Pituitary adenomas may result in considerable adverse consequences such as hormone overproduction and tumour mass effects, thus the physical and psychological conditions of patients may comprised and the quality of life (QoL) (Biamonte et al., 2021;Castellanos, Misra et al., 2021;Dallel et al., 2021). The impairment of QoL have been ensured in patients in biochemical remission of Cushing's disease (CD), non-functioning macroadenoma (NFA), acromegaly (ACRO) and prolactinoma (PRL)